Speakers at the Institute for Value-Based Medicine event held September 18, 2025, in Nyack, New York, spoke about methods of managing cardio-renal-metabolic disease.

Pirtobrutinib is now FDA-approved for relapsed/refractory CLL/SLL after prior covalent BTK inhibitor therapy, following its 2023 accelerated approval. The BRUIN-CLL-321 trial showed pirtobrutinib ...

Despite the impact of targeted treatment in oncology, much work remains to bring these therapeutics to all patients, says ...

Despite the impact of targeted treatment in oncology, much work remains to bring these therapeutics to all patients, says Bhavana (Tina) Bhatnagar, DO.

Reduced costly care: Behavioral health–related emergency department visits and inpatient admissions decreased by 35% and 43%, respectively. Lower total medical costs: The intervention group saved ...

Graff: The biggest benefit of these DTC models is [they] reduce the friction for any patient trying to receive care. It solves the problem and the multiple months in their treatment journey to receive ...

Ben Light is the vice president of partnerships at Zorro, a vendor of Individual Coverage Health Reimbursement Arrangements (ICHRAs), and an expert in ICHRAs. With ACA subsidies ending in 2025, Ben ...

The frequency of blinking can affect the stability of tear film in those living with dry eye, with the threshold of 20 blinks ...

Peter Voorhees, MD, explains how daratumumab and hyaluronidase-fihj show superior efficacy in delaying progression of MM ...

This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions ...

Members of the CAR T Vision Steering Committee outline key issues around US and EU reimbursement and discuss potential solutions ...